Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 413

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality

Open access
Shalhoub, Victoria, Shatzen, Edward M., Ward, Sabrina C., Davis, James, Stevens, Jennitte, Bi, Vivian, Renshaw, Lisa, Hawkins, Nessa, Wang, Wei, Chen, Ching, Tsai, Mei-Mei, Cattley, Russell C., Wronski, Thomas J., Xia, Xuechen, Li, Xiaodong, Henley, Charles, Eschenberg, Michael, Richards, William G.·2012·Journal of Clinical Investigation

Abstract

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is associated with secondary hyperparathyroidism (HPT) and serum elevations in the phosphaturic hormone FGF23, which may be maladaptive and lead to increased morbidity and mortality. To determine the role of FGF23 in the pathogenesis of CKD-MBD and development of secondary HPT, we developed a monoclonal FGF23 antibody to evaluate the impact of chronic FGF23 neutralization on CKD-MBD, secondary HPT, and associated comorbidities in a rat model of CKD-MBD. CKD-MBD rats fed a high-phosphate diet were treated with low or high doses of FGF23-Ab or an isotype control antibody. Neutralization of FGF23 led to sustained reductions in secondary HPT, including decreased parathyroid hormone, increased vitamin D, increased serum calcium, and normalization of bone markers such as cancellous bone volume, trabecular number, osteoblast surface, osteoid surface, and bone-formation rate. In addition, we observed dose-dependent increases in serum phosphate and aortic calcification associated with increased risk of mortality in CKD-MBD rats treated with FGF23-Ab. Thus, mineral disturbances caused by neutralization of FGF23 limited the efficacy of FGF23-Ab and likely contributed to the increased mortality observed in this CKD-MBD rat model.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci61405

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 413

Metadata

Authors
Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., Tsai, M.-M., Cattley, R. C., Wronski, T. J., Xia, X., Li, X., Henley, C., Eschenberg, M., & Richards, W. G.
Venue
Journal of Clinical Investigation
Published
2012-07-02
Volume
122
Issue
7
Pages
2543-2553
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2078730571
Cited by
413
References
42
FWCI
28.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality. https://app.cochat.ai/papers/10.1172/jci61405
The paper
Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., Tsai, M.-M., Cattley, R. C., Wronski, T. J., Xia, X., Li, X., Henley, C., Eschenberg, M., & Richards, W. G. (2012). FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality. Journal of Clinical Investigation. https://doi.org/10.1172/jci61405

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.